Aquablation Therapy Market

Aquablation Therapy Market Forecast and Outlook 2026 to 2036

The global aquablation therapy market is projected to total USD 2.08 billion in 2026, advancing to USD 5.96 billion by 2036, progressing at an 11.1% CAGR. This high-growth trajectory is propelled by the clinical and commercial adoption of this robotic, image-guided waterjet ablation technology as a differentiated standard for treating benign prostatic hyperplasia.

Key Takeaways from the Aquablation Therapy Market

• Market Value for 2026: USD 2.08 Billion
• Market Value for 2036: USD 5.96 Billion
• Forecast CAGR 2026 to 2036: 11.1%
• Leading System Type Segment (2026): Aquablation Consoles (34.2%)
• Leading Therapeutic Application Segment (2026): Benign Prostatic Hyperplasia (BPH) (68.4%)
• Leading End User Segment (2026): Hospitals (43.7%)
• Key Growth Countries: India (14.2% CAGR), Brazil (13.7% CAGR), China (13.3% CAGR), USA (10.3% CAGR), Europe (10.5% CAGR), UK (10.2% CAGR), Germany (10.1% CAGR), France (10.0% CAGR)
• Key Players: PROCEPT BioRobotics Corporation, Medtronic plc, Olympus Corporation, Boston Scientific Corporation, KARL STORZ SE & Co. KG

The procedure's ability to combine consistent tissue removal with the preservation of critical anatomical structures addresses a core limitation of earlier BPH therapies, driving its integration into urological practice. Aquablation consoles and single-use handpieces form the capital and consumable foundation of this market. The overwhelming application focus on BPH reflects the technology's primary indication and the vast, underpenetrated patient population seeking durable, minimally invasive solutions.

Hospital-based adoption leads end-user demand, supported by the need for specialized imaging and procedural support. The establishment of advanced urology centers and the rising medical demand from aging male populations fuels exceptional growth rates in emerging economies.

Aquablation Therapy Market

Metric	Value
Market Value (2026)	USD 2.08 Billion
Market Forecast Value (2036)	USD 5.96 Billion
Forecast CAGR 2026 to 2036	11.1%

Category

Category	Segments
System Type	Aquablation Consoles, Single-Use Handpieces, Imaging & Planning Software, Procedure-Specific Disposables, Service & Maintenance Contracts
Therapeutic Application	Benign Prostatic Hyperplasia (BPH), Prostate Tissue Debulking (Other), Clinical Trials & Investigational Use
End User	Hospitals, Specialty Urology Clinics, Ambulatory Surgical Centers, Academic Medical Centers
Region	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, Middle East & Africa

What Clinical and Demographic Trends are Accelerating Adoption of Robotic Ablation?

The aging global male population is directly increasing the prevalence of symptomatic BPH, creating a larger addressable patient pool seeking definitive treatment beyond medication. Rising patient awareness and demand for procedures that minimize risks to sexual and urinary function are aligning perfectly with Aquablation's clinical profile, which demonstrates low rates of retrograde ejaculation compared to thermal ablation.

The broader healthcare shift toward outpatient and short-stay surgical models favors Aquablation's potential for rapid recovery, enhancing hospital throughput and economic viability. This convergence of demographic inevitability, patient preference for functional preservation, and economic efficiency is creating a powerful adoption cycle for this technology.

Segmental Analysis

By System Type, Which Capital Equipment Enables the Core Robotic Procedure?

Aquablation consoles command a leading 34.2% share. This segment represents the high-value, durable capital equipment at the heart of the procedure. These robotic consoles integrate advanced imaging software with precise robotic control of the waterjet ablator.

Their sale or lease to hospitals and large urology clinics represents the initial market entry point and a significant revenue driver, establishing the installed base that generates recurring revenue from single-use handpieces and software upgrades.

By Therapeutic Application, Which Condition Represents the Primary Clinical Indication?

Benign Prostatic Hyperplasia treatment constitutes the dominant application segment at 68.4%. Aquablation is specifically designed and clinically validated for BPH, representing its flagship and most reimbursed indication.

The procedure’s efficacy in treating a wide range of prostate anatomies, including large glands, without imposing a size limitation common to some other minimally invasive therapies, positions it as a versatile solution for a highly prevalent condition, securing its overwhelming market share.

By End User, Which Setting Combines Surgical Infrastructure with Patient Volume?

Hospitals hold a leading 43.7% share. These institutions possess the necessary surgical infrastructure, imaging capabilities, and multidisciplinary support required for introducing a new robotic surgical platform. They also manage the high volume of referred BPH patients unsuitable for office-based therapies.

The capital investment and procedural volume are most aligned with hospital-based urology departments, which serve as the primary centers for training, procedure standardization, and complex case management.

What Forces will Influence the Commercial and Clinical Trajectory of the Aquablation Therapy Landscape?

The definitive clinical outcomes from long-term studies demonstrating Aquablation's durable efficacy and favorable functional preservation profile are overcoming initial physician skepticism, driving procedural adoption beyond early adopters.

The substantial capital investment required for the robotic console and the recurring cost of single-use handpieces present a significant economic barrier, particularly in cost-sensitive healthcare systems and smaller urology practices, potentially slowing widespread penetration.

Expansion into emerging geographic markets with growing medical tourism and private healthcare sectors offers substantial volume growth. Success in these regions depends on developing flexible capital equipment models and demonstrating cost-effectiveness through reduced operative time and length of stay.

Ongoing clinical research is actively exploring the technology's application for prostate tissue debulking in localized prostate cancer and other urological conditions, which could significantly expand the addressable market beyond BPH and attract new clinical specialties.

Analysis of the Aquablation Therapy Market by Key Countries

Country	CAGR 2026 to 2036
USA	10.3%
China	13.3%
India	14.2%
Brazil	13.7%
Germany	10.1%
France	10.0%

How does the USA's Reimbursement and Specialist Landscape Foster Adoption?

A 10.3% CAGR is underpinned by favorable Medicare reimbursement establishing a payment model, a culture of early technology adoption among urologists, and direct-to-patient marketing raising awareness.

Growth is concentrated in high-volume urology centers and hospitals competing to offer the latest minimally invasive BPH treatments, with adoption fueled by robust clinical data and specialist training programs.

What Characterizes the European Market's Regulatory and Evaluation Pathway?

Europe's 10.5% CAGR reflects a region where centralized CE marking facilitates market entry, but national health technology assessment bodies and hospital procurement committees then govern adoption.

Uptake is strong in countries with advanced healthcare systems, driven by clinical evidence and the technology’s alignment with goals of reducing surgical complications and improving patient quality of life.

Which dynamics are Central to China's Rapid Uptake in Advanced Urology?

China's 13.3% CAGR is propelled by targeted investments in upgrading urology departments in major tertiary hospitals. The technology’s robotic and image-guided nature aligns with national priorities in high-tech medicine. Growth is fueled by partnerships between global medtech firms and domestic distributors, alongside training programs for a new generation of urologists.

Why does India's Private Healthcare Sector Represent a High-Growth Frontier?

India's leading 14.2% CAGR is driven by its large, expanding private hospital sector catering to a growing middle class. These institutions compete on offering cutting-edge, minimally invasive treatments. Aquablation's appeal lies in its potential for short hospital stays and strong clinical outcomes, meeting demand for high-quality, efficient surgical care.

How is Brazil's Demographic and Healthcare Shift Influencing Market Entry?

Brazil's 13.7% CAGR is linked to its aging population and the expansion of private insurance coverage. Major urban private hospitals are key early adopters, introducing the technology to serve affluent and insured patients seeking advanced BPH care. Market development focuses on establishing training centers and proving cost-effectiveness within the private system.

What Drives Steady Adoption within Germany's Precision Medicine Framework?

Germany's 10.1% CAGR is supported by its robust healthcare infrastructure and physician affinity for engineered, precise medical technology. Adoption is evidence-based and methodical, following positive assessments from urological societies. The market values the technology’s reproducibility and data-driven planning component.

How does France's Centralized Health Technology Assessment Guide Implementation?

France's 10.0% CAGR operates within a system where the Haute Autorité de Santé assesses clinical and economic value. Positive evaluation leads to structured adoption within university hospital urology departments, which then disseminate the technique. Growth is steady and protocol-driven, following national guidance.

What Role does the UK's NHS and Specialist Commissioning Play?

NHS commissioning pathways for specialist procedures influences the UK’s 10.2% CAGR. Adoption may be concentrated in selected high-volume regional centers tasked with providing specialized BPH services. Uptake depends on demonstrating superior patient-reported outcomes and potential savings from reduced re-operation rates compared to standard therapies.

Competitive Landscape of the Aquablation Therapy Market

A technology pioneer facing encroachment from large medtech conglomerates currently defines the competitive landscape. PROCEPT BioRobotics, as the innovator, competes through deep clinical expertise, continuous software enhancement, and a focused commercial strategy.

Established players like Medtronic and Boston Scientific are developing or acquiring competing minimally invasive BPH platforms, leveraging their extensive urology sales channels and surgeon relationships. Competition centers on demonstrating superior long-term clinical data, building efficient surgeon training programs to overcome the learning curve, and creating sustainable capital equipment and consumable business models that appeal to hospital financial decision-makers.

Key Players in the Aquablation Therapy Market

• PROCEPT BioRobotics Corporation
• Medtronic plc
• Olympus Corporation
• Boston Scientific Corporation
• KARL STORZ SE & Co. KG
• Others

Scope of Report

Items	Metrics
Quantitative Units	USD Billion
System Type	Consoles, Single-Use Handpieces, Software, Disposables, Service Contracts
Therapeutic Application	BPH, Prostate Tissue Debulking, Clinical Trials
End User	Hospitals, Specialty Urology Clinics, ASCs, Academic Centers
Key Countries/Regions	India, Brazil, China, USA, Europe, UK, Germany, France
Key Companies	PROCEPT BioRobotics Corporation, Medtronic plc, Olympus Corporation, Boston Scientific Corporation, KARL STORZ SE & Co. KG
Additional Analysis	Comparative analysis of Aquablation versus laser and mechanical resection procedures; total cost of care models including retreatment rates; learning curve analysis and impact on surgeon adoption; review of real-time imaging integration and future AI applications for surgical planning.

Market by Segments

• System Type :

  • Aquablation Consoles
  • Single-Use Handpieces
  • Imaging & Planning Software
  • Procedure-Specific Disposables
  • Service & Maintenance Contracts

• Therapeutic Application :

  • Benign Prostatic Hyperplasia (BPH)
  • Prostate Tissue Debulking (Other)
  • Clinical Trials & Investigational Use

• End User :

  • Hospitals
  • Specialty Urology Clinics
  • Ambulatory Surgical Centers
  • Academic Medical Centers

• Region :

  • North America

    • USA
    • Canada

  • Latin America

    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America

  • Western Europe

    • Germany
    • France
    • UK
    • Italy
    • Spain
    • BENELUX
    • Rest of Western Europe

  • Eastern Europe

    • Poland
    • Russia
    • Czech Republic
    • Rest of Eastern Europe

  • East Asia

    • China
    • Japan
    • South Korea
    • Rest of East Asia

  • South Asia & Pacific

    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of South Asia & Pacific

  • MEA

    • GCC Countries
    • South Africa
    • Turkiye
    • Rest of MEA

Bibliography

• American Urological Association (AUA). (2025). Guideline on the Surgical Management of Benign Prostatic Hyperplasia.
• European Association of Urology (EAU). (2024). Guidelines on Non-neurogenic Male Lower Urinary Tract Symptoms.
• Gilling, P., & Barber, N. (2023). Aquablation: A Novel Robotic Waterjet Ablation Therapy for BPH. Current Urology Reports.
• PROCEPT BioRobotics Corporation. (2025). Five-Year WATER Study Clinical Data Report.
• U.S. Food and Drug Administration. (2024). Summary of Safety and Effectiveness Data (SSED): AquaBeam Robotic System.
• World Health Organization. (2024). Global Burden of Urological Disease.